Loading...
Market
Total Boehringer Ingelheim payments to Ochre Bio by end of 2025
4
Resolution / Starting Odds
Under $200 million • 25%
Between $200 million and $500 million • 25%
Between $500 million and $800 million • 25%
Over $800 million • 25%
Financial disclosures from either Ochre Bio or Boehringer Ingelheim, or financial news reports
Story
Ochre Bio, Boehringer Ink $1B Deal for Novel Liver Disease Treatments
Apr 22, 2024, 11:29 AM
Ochre Bio, a UK-based biotech startup and Y Combinator alum, has entered into a significant partnership with Boehringer Ingelheim, spearheaded by Boehringer's SVP/Global Head of Cardiometabolic Diseases Research, Søren Tullin, to develop novel regenerative treatments for chronic liver disease. This collaboration involves an upfront and near-term payment of $35 million, with potential future payments reaching up to $1 billion if certain milestones are achieved. Ochre Bio's approach, lauded for its genomics experience and innovative technology, includes analyzing thousands of donated human livers to better understand disease causes and exploring RNA modifications to enhance protein translation. Søren Tullin noted that Ochre Bio brings unique and exciting capabilities to the table, particularly in the application of advanced genomics and machine learning.
View original story
Similar markets
Less than $200 million • 25%
$200 million to $400 million • 25%
$400 million to $600 million • 25%
More than $600 million • 25%
Less than $500 million • 25%
$500 million - $1 billion • 25%
$1 billion - $2 billion • 25%
More than $2 billion • 25%
Less than $200M • 25%
$200M to $400M • 25%
$400M to $600M • 25%
More than $600M • 25%
Increase by >20% • 33%
No significant change • 33%
Decrease by >20% • 33%
Less than $500 million • 33%
$500 million to $1 billion • 33%
Greater than $1 billion • 34%
New drug candidate • 33%
FDA approval • 33%
New partnership • 33%
Below $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
Above $2 billion • 25%
Full $1.7 billion paid • 33%
Partial milestone payments made • 33%
No milestone payments made • 34%
Revenue from Imdelltra exceeds $1 billion • 25%
Revenue from Imdelltra is $500 million to $1 billion • 25%
Revenue from Imdelltra is $100 million to $500 million • 25%
Revenue from Imdelltra is less than $100 million • 25%